Asia Pacific Guillain-barre Syndrome Market Size & Outlook
Related Markets
Asia Pacific guillain-barre syndrome market highlights
- The Asia Pacific guillain-barre syndrome market generated a revenue of USD 149.8 million in 2024.
- The market is expected to grow at a CAGR of 7.9% from 2025 to 2030.
- In terms of segment, intravenous immunoglobulin (ivig) was the largest revenue generating therapeutics in 2024.
- Plasma Exchange is the most lucrative therapeutics segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 149.8 million |
| Market revenue in 2030 | USD 236.1 million |
| Growth rate | 7.9% (CAGR from 2025 to 2030) |
| Largest segment | Intravenous immunoglobulin (ivig) |
| Fastest growing segment | Plasma Exchange |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 20.5% of the global guillain-barre syndrome market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 236.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Guillain-Barre Syndrome Market Scope
Guillain-Barre Syndrome Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| LGM Pharma | View profile | 101-250 | Nashville, Tennessee, United States, North America | https://lgmpharma.com/ |
| Octapharma AG | View profile | 10001+ | Lachen, Schwyz, Switzerland, Europe | http://www.octapharma.com/en.html |
| Cadila Pharmaceuticals | View profile | 5001-10000 | Ahmedabad, Gujarat, India, Asia | http://cadilapharma.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Grifols SA Ordinary Shares - Class A | View profile | 23737 | Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 | https://www.grifols.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
Asia Pacific guillain-barre syndrome market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to guillain-barre syndrome market will help companies and investors design strategic landscapes.
Intravenous immunoglobulin (ivig) was the largest segment with a revenue share of 55.94% in 2024. Horizon Databook has segmented the Asia Pacific guillain-barre syndrome market based on intravenous immunoglobulin (ivig), plasma exchange, other therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
In the Asia-Pacific region, the GBS market is expanding rapidly, particularly in countries like China, India, Japan, and Australia. Increasing awareness of GBS and its associated risks, along with the development of healthcare infrastructure, is driving the growth of the market.
The rise in diagnosed cases across these regions is contributing to greater demand for therapies like IVIG and plasma exchange, which are crucial for managing the more severe forms of GBS, such as AIDP and AMAN.
Reasons to subscribe to Asia Pacific guillain-barre syndrome market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific guillain-barre syndrome market databook
-
Our clientele includes a mix of guillain-barre syndrome market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific guillain-barre syndrome market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific guillain-barre syndrome market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific guillain-barre syndrome market size, by country, 2018-2030 (US$M)
Asia Pacific Guillain-Barre Syndrome Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
